IMX-120 / Immix Biopharma - LARVOL DELTA

ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease (GlobeNewswire) - "Immix Biopharma, Inc...announced that it has initiated Good Manufacturing Practice ('GMP') manufacturing of IMX-120, a biologic for inflammatory bowel disease ('IBD'). ImmixBio anticipates filing an IND for IMX-120 in 2023, representing a significant milestone on ImmixBio’s path to clinical trials for IMX-120 in inflammatory bowel disease. The IBD market is expected to reach $21.4 billion by 2024 from the existing $18.4 billion in 2019."

IND • Immunology • Inflammatory Bowel Disease